OncoSec Medical Incorporated Banner Image

OncoSec Medical Incorporated has reached its limit for free report views

Work for OncoSec Medical Incorporated? Upgrade Your Profile and unlock all your annual reports.

OncoSec Medical Incorporated

  • Ticker ONCS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
OncoSec Medical Incorporated Logo Image
  • 11-50 Employees
  • Based in San Diego, California
OncoSec Medical Incorporated (the "Company," "OncoSec," "they" or "their") is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy investigational product candidate – TAVO™ (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-basedMore interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders.
OncoSec Medical Incorporated

Most Recent Annual Report

OncoSec Medical Incorporated MOST RECENT 2019 Annual Report and Form 10K

Report Locked. OncoSec Medical Incorporated has reached its limit for free report views.

Older/Archived Annual Reports